BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32673287)

  • 1. Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta.
    Liessi N; Pesce E; Braccia C; Bertozzi SM; Giraudo A; Bandiera T; Pedemonte N; Armirotti A
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32673287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
    Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
    Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Therapy for Most with Cystic Fibrosis.
    Bear CE
    Cell; 2020 Jan; 180(2):211. PubMed ID: 31978337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.
    Pinto MC; Quaresma MC; Silva IAL; Railean V; Ramalho SS; Amaral MD
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
    Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment.
    Shaughnessy CA; Zeitlin PL; Bratcher PE
    Sci Rep; 2021 Oct; 11(1):19810. PubMed ID: 34615919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
    Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
    Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
    Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW
    Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.
    Van Goor F; Hadida S; Grootenhuis PD; Burton B; Cao D; Neuberger T; Turnbull A; Singh A; Joubran J; Hazlewood A; Zhou J; McCartney J; Arumugam V; Decker C; Yang J; Young C; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu P
    Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18825-30. PubMed ID: 19846789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors.
    Saint-Criq V; Wang Y; Delpiano L; Lin J; Sheppard DN; Gray MA
    J Cyst Fibros; 2021 Sep; 20(5):843-850. PubMed ID: 34020896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Infectives Restore ORKAMBI
    Laselva O; Stone TA; Bear CE; Deber CM
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32092967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cigarette smoke activates CFTR through ROS-stimulated cAMP signaling in human bronchial epithelial cells.
    Wong FH; AbuArish A; Matthes E; Turner MJ; Greene LE; Cloutier A; Robert R; Thomas DY; Cosa G; Cantin AM; Hanrahan JW
    Am J Physiol Cell Physiol; 2018 Jan; 314(1):C118-C134. PubMed ID: 28978522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells.
    De Santi C; Fernández Fernández E; Gaul R; Vencken S; Glasgow A; Oglesby IK; Hurley K; Hawkins F; Mitash N; Mu F; Raoof R; Henshall DC; Cutrona MB; Simpson JC; Harvey BJ; Linnane B; McNally P; Cryan SA; MacLoughlin R; Swiatecka-Urban A; Greene CM
    Mol Ther; 2020 Apr; 28(4):1190-1199. PubMed ID: 32059764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
    Phuan PW; Haggie PM; Tan JA; Rivera AA; Finkbeiner WE; Nielson DW; Thomas MM; Janahi IA; Verkman AS
    J Cyst Fibros; 2021 May; 20(3):452-459. PubMed ID: 32674984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
    Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease.
    Mancini G; Loberto N; Olioso D; Dechecchi MC; Cabrini G; Mauri L; Bassi R; Schiumarini D; Chiricozzi E; Lippi G; Pesce E; Sonnino S; Pedemonte N; Tamanini A; Aureli M
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproducts.
    Adam D; Bilodeau C; Sognigbé L; Maillé É; Ruffin M; Brochiero E
    J Cyst Fibros; 2018 Nov; 17(6):705-714. PubMed ID: 29661510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells.
    Ruffin M; Roussel L; Maillé É; Rousseau S; Brochiero E
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L635-L641. PubMed ID: 29351441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.